Abstract | Although strong genetic determinants of multiple sclerosis (MS) exist, the findings of migration studies support a role for environmental factors in this disease. Through rigorous epidemiological investigation, EpsteinBarr virus infection, vitamin D nutrition and cigarette smoking have been identified as likely causal factors in MS. In this Review, the strength of this evidence is discussed, as well as the potential biological mechanisms underlying the associations between MS and environmental, lifestyle and dietary factors. Both vitamin D nutrition and cigarette smoking are modifiable; as such, increasing vitamin D levels and smoking avoidance have the potential to substantially reduce MS risk and influence disease progression. Improving our understanding of the environmental factors involved in MS will lead to new and more-effective approaches to prevent this disease.
Introduction
Multiple sclerosis (MS), like virtually all diseases, 1 is caused by many factors, the relative importance of which vary according to the given person, time and location. One purpose of epidemiological research is to identify such contingencies, particularly those that could be modifi able in a way that will improve health. This approach has enabled the prevention of dis orders such as neural tube defects, 2 sudden infant death, 3 and hepato cellular carcinoma. 4 In each case, a general hypothesis initially suggested by clinical observations or eco logical data was pursued in increasingly rigorous observational studies, culminating in experimental evidence for a causal link with disease and/or a broad public health intervention.
In MS, three environmental factors-namely infec tion with the Epstein-Barr virus (EBV), low levels of vitamin D, and cigarette smoking-are notable for the strength of evidence supporting their causal role in dis ease. Although not exhaustive, these factors could account for a large proportion of cases in the regions of highest MS incidence, and thus provide a promising foun dation for MS prevention. In this Review, we present a critical analysis of the observations that substantiate this conclusion, and outline the implications of EBV infec tion, vitamin D intake, and cigarette smoking for future research and public health interventions.
Genes and environment
MS is primarily a disease of young adults: incidence begins to rise in late adolescence, reaches a peak in indivi duals in their late 20s and early 30s, and then slowly declines, becoming rare at age 50 years and above. 5, 6 Among white nonHispanic individuals, the lifetime risk of MS is about 1 in 400. 7 The risk of disease tends to be lower in Hispanic, black, and Asian populations, 8, 9 although a recent report suggests that the risk of MS might be increasing in nonHispanic black individuals. 10 The high degree of heritability of MS was well established in studies of twins, siblings and adoptees, 11, 12 which con cluded that sharing of genes rather than environment explains the clustering of MS within families. The con cordance rate of MS is about fivefold higher in mono zygotic twins (~25%) than in dizygotic twins (~5%), and having a sibling with MS increases an individual's risk of disease 20fold to 40fold 13 compared with individuals whose close relatives are not affected by the disease.
The strongest genetic risk of MS is conferred by the HLADRB1*1501 allele, which has a 14-30% frequency in populations from countries with high MS risk, 14 and increases the risk of disease by an average of threefold in heterozygous carriers and sixfold in homozygous individuals. 15 Other HLADRB1 alleles, notably DR3 (DRB1*0301) and DR4 (DRB1*0405, DQA1*0301 and DQB1*0302), are also associated with a high MS risk. 16 The effects of these alleles, however, can explain only 20-60% of the estimated heritability of MS. 17 Numerous largescale genomewide studies and studies of multi plex families have attempted to identify the missing gen etic contributions to MS. The main findings include the likely existence of strong gene-gene interactions in the HLA region, 18 and the identification of ~25 loci asso ciated with modest increases in risk, with a relative risk between 0.8 and 1.2. 19 Given the important role of HLA in driving immune responses, these findings are consist ent with a broad role of the immune system in MS, but mostly do not provide specific insights into disease aeti ology. One exception is the discovery that rare variants of CYP27B1-the gene encoding 25hydroxyvitamin D1α hydroxylase, which converts 25hydroxyvitamin D (25[OH]D) into its active form-increases MS risk.
This finding is discussed in more detail in the vitamin D section below.
The elevated relative risk associated with having a twin or sibling with MS notwithstanding, about 80-90% of individuals with MS have a negative family history, 21, 22 a paradox that is easily explained by the overall low preva lence of MS. The fact that most individuals with MS do not have a positive family history would be insufficient to incriminate the environment, but a role for the latter is strongly supported by the geographical distribution of MS, migrationrelated changes in risk, and the results of analytical studies implicating specific risk factors.
Geography and migration
That the incidence of MS is low between the tropics and increases in frequency with increasing latitude in both hemispheres (the socalled latitude gradient) has been known for many years. 23 The overall gradient is remark able, but with several exceptions that probably occur owing to genetic influence. For example, the incidence of MS is low in the northernmost regions, which are largely inhabited by Inuit and other indigenous populations that have a low prevalence of the HLA alleles associated with MS; by contrast, MS rates are high in Sardinia, where there is a high prevalence of the MS risk alleles. Notably, among migrants from regions of high MS risk (such as the UK) to regions of low risk (such as South Africa or Australia), MS incidence seems to decrease in a graded, agerelated manner-the younger the age at immigra tion, the lower the risk-suggesting that environmental exposure early in life could be important in determining MS risk. 24, 25 A change in MS risk with migration was con firmed in a large study within the US, in which a twofold reduction in risk was found among men and women who were born in the north (>41-42 °N; regions of high MS risk), but entered military service in the south (<37 °N; regions of low MS risk). 26 By contrast, the effects of migration from lowrisk to highrisk areas have remained uncertain, partly owing to small sample sizes and methodological limita tions, which reduced the strength of the evidence. 24 For example, whereas migrants in the UK from the West Indies, the Indian subcontinent, and Africa retained their low risk of MS, 27 the incidence of MS in their UKborn children was equal to that in the nonmigrant UK popu lation. 24 Conversely, an increase in MS incidence was reported among those who migrated from the French West Indies to France. 28 A marked attenuation of the lati tude gradient, however, has been observed in the US 9, 29 and Europe. 30 In white women in the USA, a threefold higher latitude gradient was observed among those born in 1921-1946 compared with those born after 1946, among whom there was virtually no gradient. 29 The dis appearance of the latitude gradient in the US is probably due to an increased incidence of MS in the southern US, as there is no evidence that MS incidence is decreasing in the north. 6 Similarly, in Europe an increasing incidence has been reported in several southern Mediterranean regions. 31 By contrast, a strong latitude gradient per sists in the southern hemisphere. 32, 33 The reason for this 
Specific risk factors

Epstein-Barr virus
Epidemiological evidence of causality EBV, or human herpesvirus 4, is a ubiquitous double stranded DNA virus that is transmitted primarily via saliva. Infection with EBV is common and usually asymptomatic in the first years of life, but often causes an acute febrile illness, known as infectious mono nucleosis, when primary infection occurs in adolescence or adult hood, which is often the case in countries with higher socioeconomic status and hygiene. 34 Incidence of infec tious mononucleosis in a given population, therefore, reflects the distribution of age at EBV infection.
EBV infection early in life is the rule (and thus infec tious mononucleosis is rare) in the tropics and, more generally, in lowincome populations, but also in Japan, probably owing to the custom of sharing food from the same plate. 35 In the USA and Europe, the proportion of individuals who avoid early infection displays a remark able latitude gradient. For example, among cadets at the West Point Military Academy in the 1970s, the propor tion of EBVpositive individuals ranged from ~80% in those born in the south to ~50% in those born in the north. 36 Consequently, the epidemiology of infectious mononucleosis is strikingly similar to that of MS. 37 Furthermore, MS risk is twofold to threefold higher than average among individuals with a history of infectious mononucleosis. 38 These observations provided the earli est evidence that older age at EBV infection is a risk factor for MS, but are open to the alternative interpretation that good hygiene in childhood is the common link between infectious mononucleosis and MS, commonly referred to as 'the hygiene hypothesis' . 39 According to the general formulation of the hygiene hypo thesis, EBVnegative individuals, having been under exposed to earlylife infections, should have a high MS risk. However, MS risk, as inferred from crosssectional studies, seems to be extremely low in EBVnegative indivi duals. [40] [41] [42] [43] [44] Only recently have we been able to conduct a prospective investigation, relying on a repository of over 50 million serum samples collected from US military recruits. 45 As expected, only ~5% of military personnel were EBV negative at the time of the first blood collection but, owing to the large source population, the absolute number of uninfected indivi duals was sufficiently high to estimate the incidence of MS. Furthermore, as each individual provided a new blood sample every 1-2 years during their time on active duty, we were able to deter mine the approximate time of primary EBV infection. 45 The results were striking: only 10 cases of MS occurred among those individuals who were EBV negative at base line, and all of them developed the first symptoms of MS several months after serological evidence of EBV infec tion ( Figure 1) . 45 This finding virtually rules out reverse causation (that is, the likelihood that MS increases the probability of EBV infection), as well as the hypothesis that a genetic resistance to both EBV infection and MS could explain the crosssectional data. Although the pos sibility that MS could itself 'cause' EBV infection cannot be excluded, if this were the case, at least some cases of EBV infection would be expected to occur after the onset of MS symptoms. The fact that EBV infection preceded the onset of MS symptoms in all initially EBVnegative individuals argues against this scenario.
The possibility that a factor exists that can increase or decrease susceptibility to both EBV infection and MS cannot be excluded, but there are no known plausible candidates. This finding does not necessarily contra dict the hygiene hypothesis: increasing hygiene and thus reducing exposure to infections in early childhood might increase susceptibility to MS, but this susceptibil ity becomes apparent only after EBV infection, and is amplified by a late age at EBV infection. 41 In epidemiological terms, the relationship between EBV and MS resembles the relationship between hepa titis B virus and liver cancer 46 in which, despite the fact that infection increases the risk of liver cancer ~100fold, most carriers of the virus never develop liver cancer, and the disease can occur among those who are not infected. As discussed in the following section, the mechanisms that link EBV infection to MS are still uncertain. One unexploit ed epidemiological clue to this puzzle is that the risk of developing MS among apparently healthy young adults is strongly related to serum titres of antiEBV nuclear antigen (EBNA) IgG antibodies ( Figure 2 ), [47] [48] [49] [50] [51] which primarily recognize two latent EBV proteins: EBNA1 and EBNA2. In the study of US military person nel, in those who were EBV positive at the time of recruit ment, the relative risk of MS over an average followup of 5 years was 36 times higher among those with antiEBNA titres ≥320 compared with those who had titres <20.
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AntiEBNA1 antibodies are considered to be a marker of good immune response to EBV (in immunosuppres sion, EBNA1 titres decrease and EBNA2 titres tend to increase, thus inverting the EBNA1/EBNA2 ratio, which is normally >1), and tend to be higher among individuals with a history of infectious mononucleosis. 52 
Potential mechanisms
The mechanistic underpinnings of the epidemiological associations of MS and EBV are far from understood. Possible scenarios include activation and expansion of autoreactive T cells and B cells during infectious mono nucleosis (a syndrome characterized by strong immune activation), or EBVmediated immortalization of B cells, thereby leading to autoantibody production and antigen presentation to pathogenic T cells ( Figure 3 ). REVIEWS less costimulatory requirements of selfreactive lympho cytes, as well as impaired functions of regulatory immune compartments. [54] [55] [56] These findings indicate that patients with MS have lower threshold for breakdown of self tolerance to CNS antigens than do healthy individuals. Strong innate immune activation during primary EBV infection could facilitate the activation and expansion of auto reactive and polyspecific (that is, both autoantigen specific and viralantigenspecific) T and B cells. For example, patients with MS show predominant clonal expan sion of T cells that are specific for EBNA1, 57 the EBV anti gen that is most commonly targeted by CD4 + T cells in healthy virus carriers. 58 Notably, EBNA1specific T cells that recognize myelin antigens occur more frequently than do T cells that recognize self antigens not associ ated with MS. 59 Consequently, continuous restimulation of these cells owing to autoimmune tissue inflammation might contribute to the development of MS.
The profound and rapid clinical efficacy of Bcell depleting therapies reinforced the notion that Bcell func tions contribute to the pathogenesis of MS. 60 EBV persists in memory B cells and modulates their differentiation and function, 61 which may interfere with the normal process of autoreactiveBcell neutralization or control at several tolerance checkpoints during Bcell development and dif ferentiation. Furthermore, as latent EBV infection confers Bcell survival advantages that are required to pass these tolerance checkpoints, [61] [62] [63] EBV infection could assist in the survival of auto reactive Bcell species in patients with MS. Thus far, however, no experimental evidence exists to support such a hypothesis.
Owing to its immunemodifying functions in the periphery, EBV could contribute to MS development with out crossing the blood-brain barrier. Whether EBV infection drives local CNS inflammation through the presence of EBVinfected B cells and expression of viral gene products within the CNS is a matter of debate. Pre vious studies on this topic provided highly discordant results, reporting EBVinfected B cells expressing viral lytic and latency proteins in the vast majority of MS cases and lesions, or finding EBVpositive B cells only in rare cases. 64 One study, published in 2012, showed that EBVinfected B cells are present in active MS lesions but they do not express lytic viral gene products. 65 Further collaborative studies are needed to clarify whether EBV contributes to local tissue inflammation within the CNS and, if it does, by which mechanisms.
Contrary to the idea that MS development is driven by EBV infection is the hypothesis that autoreactive immune responses, or even predisposition to develop ment of such responses, enhance antiviral immune res ponses. 66 The latter scenario probably accounts for the occurrence of polyspecific antiviral humoral immune responses, which are characterized by intrathecal synthesis of antibodies against various viruses, 67-71 in the cerebro spinal fluid compartment in patients with MS, but not in healthy individuals. However, the consistent findings that sympto matic primary EBV infection increases MS susceptibility, the rarity of MS among EBVnegative individuals, and the higher sero prevalence in children and adults with MS compared with agematched peers, argues against an epi phenomenal function of EBV in MS. Studies that address potential mechanisms responsible for the reported associ ations are much needed and might lead to concepts of how EBV interferes with MS development and how alterations in EBV immunobiology could be targeted for MS therapy.
Implications for prevention and treatment
In theory, a vaccine that confers sterile immunity to EBV could protect against MS but, to our knowledge, such a vaccine is not under development. Whether the only existing vaccine-which, in a phase II trial, was shown to protect against infectious mononucleosis but not against EBV infection 72 -would reduce MS risk is uncertain. The rarity of MS among populations in which EBV infec tion occurs early in life, and the consistent finding of an increased MS risk in individuals with infectious mono nucleosis, suggest that MS risk could be reduced through voluntary early exposure of infants to EBV. A study to test this hypothesis, however, would take at least two decades, and thus is probably unfeasible. Available anti viral medications, such as DNApolymerase inhibitors, target lytic EBV infection, but have limited effects on latent EBV infection. Indeed, trials of such drugs in MS have been inconclusive. 39, 73, 74 Thus, at present, the only practical implications of EBV for MS may be diagnostic: EBV negativity or low antiEBNA titres in an individual with clinically isolated syndrome (CIS) would suggest a diagnosis other than MS. 75 
Vitamin D
Epidemiological evidence of causality
The geography of MS correlates strongly not only with age at EBV infection, but also with the duration and inten sity of UV radiation from sunlight, [76] [77] [78] which is the primary source of vitamin D in most populations. Further more, at high latitudes, where lack of sunlight during most of the year limits vitamin D synthesis, MS is less common among coastal populations that have a high intake of fatty fish-the major dietary source of vitamin D. 79 Early attempts to demonstrate an association between UV light exposure or vitamin D intake and MS have produced mixed results, probably owing to the difficulty of both recalling diet or sun exposure (often years or even decades earlier) and recruiting representative control groups. [80] [81] [82] [83] These limitations have been overcome through a combi nation of approaches that include longitudinal studies of dietary vitamin D intake in the Nurses' Health Studies 84 or of serum 25(OH)D in personnel of the US military, 85 and the use of skin actinic damage as a marker of cumulative UV light exposure in the Ausimmune study. 86 Genetic studies also support the causality of these factors in MS. 87 The relationship between vitamin D intake and MS risk was examined in two cohorts comprising 182,000 female nurses, with prospective followup for over 20 years. 84 Average vitamin D intake was assessed every 4 years using a foodfrequency questionnaire, and was validated through correlation with plasma 25(OH)D levels and an inverse relationship to risk of fractures. 88 During follow up, 173 MS cases were documented. After adjustment for age, smoking and other potential risk factors, MS risk was 40% lower among women who reported regular intake of at least 400 IU/day of vitamin D from supplements (rela tive risk [RR] = 0.60, 95% CI 0.39-0.92). Similarly, MS risk was 31% lower among women in the highest quintile of total vitamin D intake (from food and supplements) than in those in the lowest quintile.
Compared with UV light exposure, vitamin D intake is a relatively minor contributor to overall vitamin D status. As such, obtaining longitudinal data that are based on serum 25(OH)D levels, which directly reflects vitamin D status, is important. In individuals with rickets, vita min D levels are usually <30 nmol/L, and deficiency is defined as 30-50 nmol/L owing to clear associations between these levels of vitamin D and an increased level of circulating parathyroid hormone, osteoporosis and fractures. 89, 90 An emerging consensus, however, is that optimal vitamin D levels are at least 75 nmol/L. 90 For comparison, mean 25(OH)D levels among young adults in the US are about 62 nmol/L, with lower levels found in most studies in this age group in Europe and Canada. [91] [92] [93] [94] The link between serum 25(OH)D levels in apparently healthy young adults and their future risk of develop ing MS has so far been reported in only one investiga tion: a nested case-control study of activeduty military personnel, involving 257 patients with MS and 514 con trols matched by age, gender, race/ethnicity, and military branch (Army or Navy/Marines). 85 Vitamin D status was estimated as the average of the seasonadjusted serum 25(OH)D levels in two or three consecutive blood samples, collected from each individual over an average period of 5 years. The average age of study participants at the time of collection of the first blood sample was 23 years, and the mean time from the first blood collection to MS onset was 5 years. Among nonHispanic white indivi duals, the risk of developing MS was 62% lower in those in the highest quintiles of 25(OH)D levels (>99 nmol/L) than in those in the lowest quintiles (≤63 nmol/L; RR 0.38, 95% CI 0.19-0.75, P = 0.02), with similar results in men and women. By contrast, no association was found between vitamin D status and MS risk among nonHispanic black indivi duals or in those of Hispanic descent, populations in which 25(OH)D levels were, as expected, markedly low. The strong inverse association between serum 25(OH)D and MS risk among nonHispanic white individuals was not explained by differences in latitude of residence at time of recruitment, which was not itself a significant predictor of risk, and is consistent with pre vious findings support ing the disappearance of a latitude gradient of MS within the US. Although confounding of results by unmeasured factors cannot be excluded, the findings of this investiga tion strongly suggest that high levels of serum 25(OH)D in young adults could reduce MS risk, independently of vitamin D status during childhood. If this association reflects a protective effect of vitamin D, one would expect that a substantial proportion of MS cases in northern regions of the USA could be prevented by vitamin D sup plementation, with an even greater proportion of people being likely to benefit from this approach in the UK and other European countries, where average 25(OH)D levels are much lower. 94 The results of the longitudinal studies described above were corroborated by an investigation in Australia in which the degree of actinic damage in the dorsum of the hand was used as a marker of cumulative lifetime sun exposure. 86 A lower degree of actinic damage was found at the time of onset of a first demyelinating event (FDE) among 216 MS cases compared with 395 matched con trols selected at the same latitude, with an odds ratio of 0.39 for an FDE in individuals in the category of highest actinic damage compared with those in the category of lowest actinic damage (95% CI 0.17-0.92). In the same study, an inverse association was found between serum 25(OH)D levels and incidence of FDEs (odd ratio 0.92 for a 10 nmol/L increase in 25(OH)D, 95% CI 0.86-1.00). Both actinic damage and 25(OH)D contributed to FDE risk in the same model, suggesting that the two measure ments might provide complementary information: 25(OH)D levels reflecting recent exposure, and actinic damage indicating cumulative longterm exposure. 95 UV light exposure, in addition to being the strongest determinant of serum 25(OH)D levels in most popula tions, also has direct effects on the immune system. 96 Such effects have not been extensively investigated in humans, so the degree to which they might contribute to lowering the risk of MS remains uncertain. Two important pieces of evidence, however, suggest that the lower MS risk among individuals with high levels of 25(OH)D is medi ated by vitamin D, rather than other effects of UV light: one is the finding from a longitudinal study (described above) that MS risk was lower among women who regu larly took vitamin D supplements compared with women who did not take supplements; 84 the other is the associa tion between mutations in CYP27B1, which encodes the enzyme that converts 25(OH)D to its active form, and MS risk. 20, 97, 98 Rare nonfunctional variants of CYP27B1 have been identified that cause vitamin Ddependent rickets type1 in homozygous carriers. 99 Compared with the general population, a markedly increased MS risk has been reported not only among individuals with this form of rickets, 100 but also among individuals who are heterozygo us carriers of mutations in CYP27B1. 20 Collectively, the results support the importance of vitamin D sufficiency in adolescence and adulthood, up to the time of MS onset, but do not exclude the possible importance of vitamin D in childhood or even in utero. Consistent with a role for vitamin Dmediated effects in childhood are the results of migration studies 24, 25 and the increased risk of MS associated with obesity (a cause of vitamin D insufficiency) in adolescence. 101, 102 The potential importance of vitamin D in utero is suggested by preliminary findings of a low MS risk among women whose mothers took vitamin D supplements during pregnancy, 103 and by variations in MS risk according to month of birth. 104, 105 Notably, factors other than vitamin D (such as infection) also vary seasonally, and could explain the month of birth association with MS risk. The results from childhood and in utero studies, however, are far from conclusive, and do not affect the strong evidence supporting the importance of vitamin D levels in adulthood in affecting MS risk.
Mechanisms
How vitamin D may exert a protective effect on MS risk is unknown, but the body of literature on the immuno modulatory effects of vitamin D is growing, and this aspect of vitamin D biology could be relevant for MS. The vast majority of research in this area, however, has been in animal models or in vitro, and may or may not reflect the effects of vitamin D in humans.
Few randomized clinical trials have been performed in which individuals were given vitamin D supplements (in cholecalciferol form) and immunological changes studied; only one of these studies was done in healthy indivi duals, 106 the remaining studies being in patients with MS, 107-109 obese individuals, 110 or in patients with congestive heart failure. 111 The studies varied with res pect to the dose and duration of vitamin D supplemen tation and average levels of 25(OH)D achieved (Figure 4) . The upper boundary of the physiological range of 25(OH)D (that is the range observed in healthy indivi duals who do not take vitamin D supplements) is around 150 nmol/L. 112, 113 Collectively, four of the trials examined immunological changes when supplementation achieved 25(OH)D levels of, on average, 70-145 nmol/L. 106, 107, 110, 111 In healthy individuals, 106 a statistically significant increase from 5% to 6% in the proportion of regulatory T cells was observed in the vitamin D supplemented group (140,000 IU/month for 3 months), whereas no increase was seen in the placebo group. In MS patients given 1,000 IU/day for 6 months, 107 serum levels of transforming growth factorβ1 were increased, but no statistically significant changes in mRNA levels of IL2, tumour necrosis factor, IFNγ, or IL13 were observed in peripheral blood mononuclear cells. A decrease in serum tumour necrosis factor and an increase in serum IL10 was observed in a study of patients with congestive heart failure who received 2,000 IU/day for 9 months, 111 but no change in IL10 levels was observed in a trial of obese individuals given either 40,000 IU or 20,000 IU/week for 1 year. 110 Immunological responses were also measured in two trials involving patients with MS who were given doses of cholecalciferol that raised the average 25(OH)D into the supraphysiological range (average ~400 nmol/L) for a brief period of time. 108, 109, 114 In one study, no differences in serum cytokine levels were observed over 12 weeks, but Tcell proliferation in response to stimulation with MSrelated antigens and dietary antigens was decreased. 108 In the other study, the total number of circulating total or regulatory Tcells was unchanged after 12 weeks of sup plementation with 20,000 IU cholecalciferol per day, but the number of IL10 + CD4
+ T cells was increased and the IFNγ + CD4 + :IL4 + CD4+ Tcell ratio was decreased. 109 
DISEASE MECHANISMS IN MS
Furthermore, low plasma levels of Bcellactivating factor were observed after 12 weeks 114 ( Figure 4 ). Other immunomodulatory effects of vitamin D obser ved in vitro or in animal models include reduc tions in anti inflammatory cytokine production and MHC presentation by antigenpresenting cells; decreases in Th1 and Th17 cell populations, with reduced expression of related cytokines including IFNγ and IL17; and decreased plasmacell conversion and antibody production by B cells. These observations are reviewed in detail else where. 115 More in vivo studies of these effects and associated 25(OH)D levels in humans are needed to fully understand the mecha nism underlying vitamin D supple mentation and MS risk reduction. Vitamin D might also influence MS risk indirectly through its enhancing effect on micro bicidal responses 116 and ability to reduce risk of respira tory infections, 117, 118 which are known triggers of MS relapses [119] [120] [121] and may have some influence on MS risk. as well as the potential risks associated with supplementa tion, such as an increased incidence of kidney stones. 125 Available data suggest that MS risk is minimized at an average serum 25(OH)D level above 100 nmol/L, 85 a level currently achieved by only onefifth of the atrisk population in the US, and a smaller proportion in most atrisk European populations. 94 This level of vitamin D could be reached in most adolescents and adults by taking 2,000-4,000 IU/day of vitamin D3 126, 127 -a dose that is well above current recommendations, but considered safe. 128 Little specific information currently exists on genetic interactions between vitamin D intake and vitamin D levels or the biological effects of vitamin D, and owing to the safety and low cost of vitamin D, dose individualiza tion is probably unnecessary. Most importantly, given the uncertainties and the high stakes involved, experimental evidence to show beneficial effects should be pursued before implementing nationwide universal vitamin D supplementation programmes, or evidence should at least be sought in parallel with such implementation. By con trast, for individuals at high MS risk owing to their family history, those who have experienced a CIS, and those with MS, use of vitamin D supplements is arguably a rational choice, considering the strength of the evidence and the low risk of adverse events, and given the years of research that will be required to obtain more conclusive evidence.
Cigarette smoking
Compared with never smokers, MS risk in ever smokers is ~50% higher, and risk is directly associated with smoking duration and intensity. [129] [130] [131] [132] [133] In a longitudi nal study in two large cohorts of nurses, 129 MS risk was about twofold higher among women who smoked ≥25 packyears (equivalent to smoking one pack of cigarettes per day for over 25 years) than in never smokers. The adverse effect of smoking on MS risk seems even higher among men than women, with some studies reporting a nearly threefold increase in risk in male ever smokers compared with male never smokers. [133] [134] [135] Differential changes in smoking behaviour between men (with decreased numbers of smokers) and women (with a rela tively constant number of smokers) over the past several decades (Figure 5a ) can explain most of the increase in the female:male ratio in MS incidence noted in Canada, 136 
Denmark
137 and other regions. 138 Indeed, assuming that the relative risk of smoking in men versus women is ~2.7, this change in smoking behaviour alone could explain most of the increase in the female:male ratio in MS incidence (Figure 5b) . 138 An important caveat, however, is that these changes in smoking behaviour would predict that the decrease in MS incidence in men, rather than the increase in women, is driving the increasing female to male ratio in MS incidence. 137 Together, these results suggest that the decrease in smoking behaviour among men is offsetting the adverse effects of some other factors, perhaps improved hygiene 39 or age at EBV infection, that are acting on both genders. 138 Numerous mechanisms have been proposed to explain the adverse effects of smoking on MS risk, including effects on demyelination, 139, 140 disruption of the bloodbrain barrier, 141 immunomodulatory effects, 142, 143 and increased nitric oxide and nitric oxide metabolites, 144 but all remain speculative. The observation that tobacco smoking, but not Swedish tobacco snuff, is strongly associ ated with an increased MS risk, suggests that c ombustion or inhalation are required for toxicity. 133 
Integration of risk factors
Epidemiological studies suggest that EBV infection or markers of immune response to EBV infection (namely, infectious mononucleosis and antiEBNA titres), vitamin D insufficiency, and smoking increase MS risk independently of one another 51, 145 and genetic suscepti bility. 146 In this context, 'independently' means that the relative risk associated with each factor remains con stant across all levels of the remaining factors. Thus, the expected risk of an individual who smokes ≥25 packyears (RR = 1.7), is vitamin D deficient (RR = 2.0), and has a history of infectious mononucleosis (RR = 2.3), would be ~8 times (1.7 × 2.0 × 2.3) higher than that of an indivi dual without any risk factors. The strongest nongenetic risk factor for MS remains the level of antiEBNA antibodies, with about a 30fold increase between the lowest and highest EBNA IgG titre levels found among indivi duals who are EBV positive. In the extreme, risk of MS could vary by more than 200fold (8 × 30) according to the pres ence or absence of known nongenetic risk factors, and by more than 400fold if the HLADRB1*1501 genotype is considered. This high relative risk, however, is driven by the fact that indivi duals without any risk factors have an extremely low risk of MS, and it remains difficult to identify individuals at high absolute risk of MS, with the exception of monozygotic twins of individuals with MS.
Conclusions and future directions
During the past decade, substantial progress has been made in understanding the risk factors for MS. Vita min D supplementation and smoking cessation are immediately available interventions that are likely to reduce MS risk and improve the outcomes of indivi duals with CIS or MS. Further benefits could be achieved by exposing infants to EBV infection, but remaining uncer tainty and current societal norms do not favour this type of intervention. In the short term, further observational studies, as well as randomized trials of vitamin D, should provide moredefinitive evidence as to who should take supplements, when, and how much, not only for primary prevention, but also for secondary prevention and treat ment. In the long term, an indepth elucidation of how EBV interferes with the development of MS could lead to new approaches to prevention and treatment. 
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